A股異動丨萬泰生物逆勢漲4.61% 二價HPV疫苗獲得摩洛哥上市許可
格隆匯5月12日丨萬泰生物逆勢漲4.61%,報175.68元,暫錄3連漲,總市值1546億元。萬泰生物昨晚公佈,近日,公司全資子公司廈門萬泰滄海生物技術有限公司自主研發的雙價人乳頭瘤病毒疫苗(大腸桿菌)(“二價HPV疫苗”)獲得摩洛哥國家衞生和社會保障部的上市許可批准。此次獲得摩洛哥上市許可,是公司的二價HPV疫苗獲得的首個境外上市許可,標誌着該產品可正式出口到摩洛哥,將對公司開拓國際市場帶來積極影響,有利於進一步提升公司產品的國際競爭力。公司二價HPV疫苗目前的年產能為3000萬支,公司未來將根據市場需求情況提升產能。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.